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Monocytes play an important role in the regulation of alloimmune responses after heart
transplantation (HTx). Recent studies have highlighted the importance of immunometabolism in
the differentiation and function of myeloid cells. While the importance of glucose metabolism in
monocyte differentiation and function has been reported, a role for fatty acid β-oxidation (FAO)
has not been explored. Heterotopic HTx was performed using hearts from BALB/c donor mice
implanted into C57BL/6 recipient mice and treated with etomoxir (eto), an irreversible inhibitor of
carnitine palmitoyltransferase 1 (Cpt1), a rate-limiting step of FAO, or vehicle control. FAO inhibition
prolonged HTx survival, reduced early T cell infiltration/activation, and reduced DC and macrophage
infiltration to heart allografts of eto-treated recipients. ELISPOT demonstrated that splenocytes
from eto-treated HTx recipients were less reactive to activated donor antigen-presenting cells. FAO
inhibition reduced monocyte-to-DC and monocyte-to-macrophage differentiation in vitro and
in vivo. FAO inhibition did not alter the survival of heart allografts when transplanted into Ccr2deficient recipients, suggesting that the effects of FAO inhibition were dependent on monocyte
mobilization. Finally, we confirmed the importance of FAO on monocyte differentiation in vivo
using conditional deletion of Cpt1a. Our findings demonstrate that targeting FAO attenuates
alloimmunity after HTx, in part through impairing monocyte differentiation.
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Heart transplantation (HTx) is the preferred treatment for numerous patients with end-stage heart failure;
it provides a median survival of approximately 12 years and a significant improvement in quality of life
(1, 2). Calcineurin inhibitors (FK506; cyclosporine) remain the primary immunosuppressive agent, despite
the advent of newer immunosuppressants, such as mTOR inhibitors (rapamycin [sirolimus]; everolimus)
or costimulation blockers (anti–CTLA4-immunoglobulin; belatacept). All these immunosuppressive agents
(including the adjuvant therapies of corticosteroids and mycophenolic acid) mechanistically target T cell
proliferation, and, despite robust suppression of acute T cell responses that have led to dramatic reductions
in acute rejection, chronic allograft rejection remains.
During acute inflammation, classical monocytes are mobilized from the bone marrow and migrate to
sites of injury (3). Monocytes can respond to factors such as granulocyte macrophage colony-stimulating
factor (GM-CSF) or macrophage colony-stimulating factor (M-CSF), among other factors, to differentiate
into monocyte-derived cells that have phenotypic similarities to DCs and macrophages (4–7). In acute kidney allograft rejection, monocyte infiltration has been quantitatively associated with renal dysfunction (8),
and monocyte-mediated acute renal rejection has been reported after inhibition of T cell infiltration by
alemtuzumab (9). A higher number of CD16+ monocytes before transplant was associated with higher risk
of acute rejection after kidney transplantation (10). The monocyte-macrophage lineage is central to allograft
rejection, contributing to alloimmunity via multiple mechanisms, including antigen processing/presentation,
costimulation, and proinflammatory cytokine production (11, 12). CD16+ monocyte infiltration and polarized M2 macrophages in endomyocardial biopsies have been associated with acute cellular rejection in
human heart transplants (13). Monocyte-derived DCs have also been reported to impair early graft function
in islet transplantation (14) and can promote cardiac allograft rejection (15).
1
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Immunometabolism, the study of the role of metabolic pathways in immune cells, has recently
emerged as a central regulator of immune cell differentiation and function (16–22). To date, a role for
fatty acid β-oxidation (FAO) has not been explored in monocyte differentiation. Much of our insight on
the role of oxidative metabolism has been garnered through in vitro analysis of cells using extracellular
flux analysis, which only provides an assessment of oxygen consumption and extracellular (media) acidification as a surrogate for lactate production based on substrate utilization in the presence and absence of
metabolic inhibitors (16, 20, 23). In this study, we aimed to test the effect of pharmacological inhibition of
FAO using etomoxir (eto), an irreversible inhibitor of carnitine palmitoyltransferase 1 (Cpt1), a rate-limiting step of FAO, in a murine model of acute heart allograft rejection. Further, we verified the importance
of FAO in monocyte differentiation in vivo using conditional deletion of Cpt1a.

Results
Pharmacological inhibition of FAO extends HTx survival. To investigate the role of FAO in HTx rejection, we
performed syngeneic (C57BL/6 [B6] → B6) and allogeneic (BALB/c [BALB] → B6) murine heterotopic
cardiac transplants. Pharmacological inhibition of FAO with eto starting on the day of transplantation
significantly prolonged allograft survival compared with treatment with vehicle control (ctrl) (median
graft survival: 13 versus 8 days in eto- vs. ctrl-treated HTx; Figure 1A). Histological analysis 4 days after
transplant revealed reduced immune cell infiltration in eto-treated HTx recipients (Figure 1B). To further define the cellular infiltrate preceding acute heart allograft rejection, flow cytometric analysis was
performed on day 4 after transplant. This revealed a significant reduction in the abundance of T cells,
activated T cells, CD4+ T cells, CD8+ T cells, and Foxp3+CD4+ T cells consistent with the phenotype of
regulatory CD4+ T cells (Tregs) in transplanted hearts from eto-treated HTx recipients compared with
ctrl-treated HTx recipients (Figure 1, C–G). We did not observe a difference in the ratio of CD4+ to CD8+
T cells in transplanted hearts between the 2 groups (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.151596DS1). We also observed a significant reduction in CD11b+CD64+CD24– macrophages and CD11c+MHCII+CD64– DCs in transplanted
hearts from eto-treated HTx recipients compared with ctrl-treated HTx recipients (Figure 2, A and B). In
line with this observation, allografts from eto-treated HTx recipients had significant reductions in both
recipient-derived macrophages and DCs (Figure 2, C and D). Analysis of FAO inhibition in syngrafts did
not reveal any significant differences in infiltrating leukocytes relative to the syngrafts receiving vehicle ctrl
(Supplemental Figure 1, B–H).
Inhibition of FAO reduces alloreactivity after HTx. We observed significant reduction in IFN-γ, TNF-α,
and IL-2 production in splenocytes isolated from eto-treated HTx compared with ctrl-treated HTx recipients when stimulated with donor- but not recipient-derived antigen-presenting cells (APCs) (Figure 3 and
Supplemental Figure 2, A–C). In vitro inhibition of FAO in splenocytes from ctrl-treated HTx recipients
did not alter IFN-γ production when stimulated with positive ctrl (concanavalin A) or donor-derived
APCs (Supplemental Figure 2, D and E), indicating that the effect of FAO in vivo is not likely due to
direct T cell inhibition. Furthermore, FAO inhibition in splenocytes that were isolated from ctrl-treated
HTx allograft recipients did not alter their proliferative responses after stimulation with donor-derived
APCs (Supplemental Figure 2F).
FAO inhibition impairs monocyte differentiation after HTx. We next sought to investigate whether FAO
plays a role in monocyte differentiation. To this end, we differentiated bone marrow–derived monocytes
toward DC (GM-CSF + IL4) and macrophage (M-CSF) fates in the presence or absence of 100 μM eto
for 7 days. Pharmacological inhibition of FAO significantly impaired the generation of cells with dendritic
(Figure 4A) and macrophage (Figure 4B) phenotypes. Analysis of proliferation did not reveal any significant differences between eto- and ctrl-treated cells toward either fate (Supplemental Figure 3, A and B). Our
investigation of central carbon flux in monocytes showed a significant increase in FAO flux after 48-hour
incubation following either GM-CSF + IL4 or M-CSF stimulation, which was sharply inhibited by pharmacological inhibition of FAO (Figure 4C). Inhibition of FAO flux in monocytes by eto was confirmed for
a range of doses from 5 to 100 μM (Supplemental Figure 3C). Furthermore, Cpt1 activity assay was used
to verify the ability of eto to impair both palmitate and palmitoyl-CoA transport into isolated mitochondria
from murine monocytes (Figure 4, D and E). Stimulation of monocytes with either GM-CSF + IL4 or
M-CSF significantly increased both glycolytic flux (Supplemental Figure 3D) and cell proliferation (Supplemental Figure 3E). We did not observe any increased cell death due to inhibition of FAO, as assessed by
JCI Insight 2022;7(7):e151596 https://doi.org/10.1172/jci.insight.151596
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Figure 1. FAO inhibition improves HTx survival and decreases T cells in the transplanted heart. (A) Comparison of graft survival in vehicle-treated (ctrl-treated)
or etomoxir-treated (eto-treated) BALB → B6 heart allografts. The survival benefit was significant (****P < 0.0001 by Mantel-Cox test). (B) Representative
micrographs from 4 days after transplant showing reduced immune cell infiltration in allografts from eto- compared with ctrl-treated HTx (original magnification,
×20). (C–G) Flow cytometric assessment in transplanted hearts from BALB → B6 heart allografts 4 days after transplant, shown as a percentage of CD45+ cells (left
graph) or live cells (right graph). (C) Pan T cells assessed by CD3+CD90.2+ cells (ctrl, n = 8; eto, n = 7). (D) Activated T cells assessed by CD69+CD3+CD90.2+ cells (ctrl, n
= 8; eto, n = 7). (E) CD4+ T cells assessed by CD4+CD3+CD90+ cells (ctrl, n = 8; eto, n = 7). (F) CD8 T cells assessed by CD8+CD3+CD90.2+ cells (ctrl, n = 8; eto, n = 7). (G)
Tregs assessed by Foxp3+CD4+CD3+CD90.2+ cells (ctrl, n = 5; eto, n = 5). Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 by t test.

lactate dehydrogenase (LDH) enzyme release, and FAO inhibition in GM-CSF + IL4-treated monocytes
reduced LDH release, suggesting decreased cell death (Figure 4F).
To investigate the role of FAO on monocyte differentiation in vivo, we adoptively transferred CD45.1+
monocytes at the time of HTx into eto- or ctrl-treated recipients (Figure 5A). We observed significant
JCI Insight 2022;7(7):e151596 https://doi.org/10.1172/jci.insight.151596
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Figure 2. FAO inhibition reduces macrophages and DCs in the transplanted heart. Flow cytometric assessment in vehicle-treated (ctrl-treated) or
etomoxir-treated (eto-treated) BALB → B6 heart allografts 4 days after transplant shown as a percentage of CD45+ cells (left graph) or live cells (right
graph). (A) Macrophages assessed by CD11b+CD64+CD24– cells (ctrl, n = 8; eto, n = 7). (B) DCs assessed by CD11c+MHCII+ cells (ctrl, n = 5; eto, n = 5).
(C) Recipient-derived macrophages assessed by IA-b+CD11b+CD64+CD24– cells (ctrl, n = 8; eto, n = 7). (D) Recipient-derived DCs assessed by
IA-b+CD11c+MHCII+ cells (ctrl, n = 5; eto, n = 5). Data are shown as mean ± SEM. *P < 0.05; **P < 0.01 by t test.

reductions in CD45.1+ DCs and CD45.1+ macrophages in the allograft hearts of eto-treated recipients compared with that in ctrl-treated recipients (Figure 5, B and C). There were comparable abundances of Ki-67+
proliferating monocyte-derived cells in allografts between eto- and ctrl-treated recipients (Supplemental
Figure 4, A and B), and no significant differences in the relative abundance of CD45.1+ cells in transplanted hearts, native hearts, spleens, or mediastinal lymph nodes (Supplemental Figure 4C). Moreover,
the relative abundances of CD45.1+ DCs or CD45.1+ macrophages were comparable in the native hearts,
spleens, and mediastinal lymph nodes of eto- and ctrl-treated HTx recipients (Supplemental Figure 4, D
and E). Analysis of CD45.2+ DCs and macrophages revealed a significant reduction in these populations in
transplanted hearts from eto-treated HTx recipients compared with those from ctrl-treated HTx recipients
(Supplemental Figure 4, F and G).
HTx survival benefit from FAO inhibition is abrogated in Ccr2–/– recipients. To further assess whether the HTx
survival benefit observed from pharmacological inhibition of FAO was related to its effects on monocytes,
we transplanted BALB hearts into B6 Ccr2-deficient (Ccr2–/–) recipients. We and others have shown that
monocyte mobilization from the bone marrow is dependent on Ccr2 (24–26). Consistent with observations from previous reports, we observed a modest prolongation in allograft survival when recipients lack
Ccr2 (27, 28). Importantly, heart allograft survival in Ccr2–/– recipients was independent of FAO inhibition
(median HTx survival, 14 versus 14 days after transplant in ctrl- versus eto-treated Ccr2–/– HTx; Figure 6A).
Of note, the median survival of hearts that were transplanted into either ctrl- and eto-treated Ccr2–/– HTx
recipients was comparable to BALB hearts transplanted into WT B6 allogeneic hosts that were treated
with eto. We observed similar relative abundances of total and activated T cells within transplanted hearts
JCI Insight 2022;7(7):e151596 https://doi.org/10.1172/jci.insight.151596
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Figure 3. FAO inhibition reduces alloreactivity after HTx. ELISPOT assay performed using splenocytes procured 4 days after transplantation from vehicle-treated
(ctrl-treated) or etomoxir-treated (eto-treated) BALB →B6 heart allografts. Samples were stimulated with donor-derived (BALB) APCs and assessed for the production of (A) IFN-γ (ctrl, n = 6; eto, n = 8), (B) TNF-α (ctrl, n = 4; eto, n = 4), or (C) IL-2 (ctrl, n = 4; eto, n = 4). Data are shown as mean ± SEM. *P < 0.05 by t test.

between ctrl- and eto-treated Ccr2–/– HTx recipients, which were also comparable to our observations in
cardiac allografts after transplantation into eto-treated B6 recipients (Figure 6, B and C). Additionally, there
were no significant differences in the relative abundances of DCs, macrophages, CD4+ or CD8+ T cells, or
Tregs in allografts in eto- versus ctrl-treated Ccr2–/– HTx recipients, suggesting that the reduction in these
immune cell populations induced by FAO inhibition in BALB to B6 HTx were secondary to the presence of
Ccr2+ cells in the transplant recipient (Figure 6, D and E, and Supplemental Figure 5, A–C). As expected,
heart allografts from Ccr2–/– HTx recipients had significantly reduced numbers of DCs compared with heart
allografts from BALB → B6 HTx recipients, with a trend toward reduced numbers of macrophages (Figure
6, D and E). Further, investigation of recipient-derived populations of DCs and macrophages revealed a
robust decrease in these populations in BALB → Ccr2–/– HTx recipients (Supplemental Figure 5, D and
E). Finally, assessment of T cell alloreactivity showed no significant differences between splenocytes from
ctrl- and eto-treated Ccr2–/– HTx recipients when stimulated with donor- or recipient-derived APCs (Figure
6F and Supplemental Figure 5F).
Genetic deletion of Cpt1a in monocytes impairs monocyte differentiation after HTx. To further confirm the
importance of FAO in monocyte differentiation, we generated transgenic mice with conditional deletion of
Cpt1a in monocytes (Ccr2.CreER;Cpt1afl/fl, referred to herein as Ccr2ΔCpt1a mice). Littermate Cre–, Cpt1afl/fl mice
were used as ctrls (referred to herein as WT mice). We adoptively transferred WT or Ccr2ΔCpt1a monocytes
into HTx recipients (CD45.1+ BALB heart to CD45.1+ B6 recipient) at the time of transplantation (Figure
7A) and observed significant reductions in the relative abundance of CD45.2+ DCs and CD45.2+ macrophages in transplanted hearts from recipients adoptively transferred with Ccr2ΔCpt1a compared with WT
monocytes (Figure 7, B and C). In vivo deletion of Cpt1a in Ccr2-expressing cells did not alter monocyte
numbers in the bone marrow (Supplemental Figure 6A). Assessing Ki-67+ proliferating cells from transplanted hearts in recipients adoptively transferred with WT or Ccr2ΔCpt1a monocytes revealed no significant
difference in Ccr2ΔCpt1a monocyte-derived DCs or Ccr2ΔCpt1a monocyte-derived macrophage Ki67 positivity
compared with WT counterparts (Supplemental Figure 6, B and C). Finally, we did not observe a difference in CD45.2+ cells in the transplanted hearts of HTx recipients adoptively transferred with either
Ccr2ΔCpt1a monocytes or WT monocytes (Supplemental Figure 6D).

Discussion
In our current study, we demonstrate that pharmacological inhibition of FAO significantly prolongs
heart allograft survival. Adoptive transfer experiments revealed that FAO inhibition results in a significant impairment in monocyte differentiation, which results in a reduction of monocyte-derived DCs and
macrophages in the transplanted heart, with no impairment on the homing of monocytes to the heart
allograft. In vitro experiments confirmed that FAO inhibits monocyte differentiation, while not directly
affecting T cell reactivity. Eto did not extend allograft survival in Ccr2–/– recipients, further supporting
FAO-mediated dampening of alloimmunity through its effects on monocytes. Finally, genetic deletion
of Cpt1a in monocytes mirrored effects on monocyte differentiation in heart allografts observed with
JCI Insight 2022;7(7):e151596 https://doi.org/10.1172/jci.insight.151596
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Figure 4. FAO inhibition impairs monocyte-to-DC and monocyte-to-macrophage differentiation in vitro. (A and B) Flow cytometric assessment of
monocytes after 7-day culture, shown as a percentage of CD45+ cells. (A) DCs assessed by CD11c+MHCII+CD64– cells (ctrl, n = 9; eto, n = 9). (B) Macrophages
assessed by CD11b+CD64+CD24– cells (ctrl, n = 9; eto, n = 9). (C) FAO flux in monocytes in media only or treated for 48 hours with GM-CSF + IL4 (DC differentiation condition) or M-CSF (macrophage differentiation condition), as assessed by [9,10-3H]palmitic acid radioisotopic incorporation (ctrl, n = 9; eto,
n = 9). (D and E) Cpt1 activity assay in intact mitochondria from monocytes treated with 10 or 100 μM etomoxir or 100 μM malonyl-CoA coincubated with
either (D) 9,10-[3H]palmitic acid (n = 4) or (E) 1-[14C]palmitoyl-€ (n = 4). (F) Cell death in monocytes in media only or treated for 48 hours with GM-CSF + IL4
or M-CSF, as assessed by lactate dehydrogenase (LDH) release (ctrl, n = 9; eto, n = 9). Data are shown as mean of individual data points from 3 independent experiments ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by (A and B) t test or ANOVA and (C–F) Bonferroni’s post hoc test.

pharmacological inhibition of FAO. Collectively, these findings present a possibly previously unreported
role for FAO in monocyte differentiation in the context of the regulation of alloimmunity.
Due to a reported role of glycolysis in macrophages and DCs, with sparse reports on specific oxidative metabolic pathways, we sought to investigate the role of FAO on heart allograft rejection. FAO has
been reported to support an LPS-induced phenotype resembling the Warburg effect in glucose-deprived
monocytes (23). However, this conclusion was primarily supported by results obtained by extracellular flux
analysis. Raulien et al. reported that glutamine and fatty acids drive oxidative metabolism in the absence
of glucose, and, for FAO, this occurs at the expense of lipid droplets (23). While this altered metabolic
state in glucose deprivation is reported to provide sufficient energy to sustain functional properties such as
cytokine secretion, migration, and phagocytosis, it does not prevent a rise in AMP/ATP ratio or decreased
respiratory burst (23). In the context of aging, monocytes are key producers of inflammatory cytokines,
and monocytes from aged individuals were found to contain high levels of lipid droplets and impaired
FAO, in part, through the downregulation of peroxisome proliferator–activated receptor-α (29), supporting
the importance of FAO in monocyte function.
It is important to note that glycolysis is important in monocyte functions, including their activation
and adhesion (30), and also plays a role in modulating CD8+ T cell function in human Chagas disease (31)
JCI Insight 2022;7(7):e151596 https://doi.org/10.1172/jci.insight.151596
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Figure 5. FAO inhibition impairs monocyte-derived DC and monocyte-derived macrophage differentiation in heart allografts in vivo. (A) Schematic representation of adoptive transfer of 107 CD45.1+ monocytes isolated from Pepboy mice intravenously injected into HTx recipients at the time of engraftment.
(B and C) Flow cytometric assessment of BALB → B6 heart allografts 4 days after HTx that were adoptively transferred with CD45.1+ monocytes at the
time of transplantation. Cell subtypes are shown as a percentage of CD45.1+ cells. (B) CD45.1+ DCs assessed by CD11c+MHCII+CD64– cells (ctrl, n = 4; eto,
n = 5). (C) CD45.1+ macrophages assessed by CD11b+CD64+CD24– cells (ctrl, n = 4; eto, n = 5). Data are shown as mean ± SEM. *P < 0.05; **P < 0.01 by t test.

and neutrophils in human hepatocellular carcinoma (32). Lee et al. demonstrated that LPS stimulation
increases the rate of glycolysis in human classical monocytes and that 2-deoxyglucose–mediated inhibition
of glycolysis impaired LPS-induced activation and adhesion of monocytes (30). In this setting, increased
glycolysis was regulated by mTOR-induced glucose transporter 1 expression, which subsequently led to
increased accumulation of reactive oxygen species and activation of p38 MAPK, resulting in subsequent
activation and adhesion of monocytes. However, these studies did not explore a direct role for FAO in
monocyte function, in particular, in the context of an in vivo allogeneic environment.
As with all pharmacological approaches, FAO inhibition by eto would be expected to also affect
other cell types that may be reliant on FAO, including cardiomyocytes (33), skeletal muscle cells (34),
endothelial cells (35–37), and renal tubular epithelial cells (38). Within immune cell subsets, FAO has
also been reported to be important in macrophage polarization (39) and CD8+ T memory (Tmem) cells
(40); however, recent evidence using genetic models has brought into question the specific requirement
for Cpt1a or long-chain FAO in M2 macrophage polarization (41) and Tmem cells (42, 43). Consistent
with reports that Cpt1a/FAO is dispensable in T cells (42, 43), we did not observe direct effects of
pharmacological inhibition of FAO on T cell activation. Eto has been shown to affect antigen-stimulated
IL-15 Tmem-like cells in vitro (44); however, genetic studies targeting FAO enzymes revealed no impairment in Tmem cell formation in vivo (42). In our work, we did not investigate Tmem cells; however, the
abrogation of survival benefit and T cell changes in Ccr2–/– recipient mice support the hypothesis of a
FAO-dependent role in monocytes or monocyte-derived cells in our experiments. Administration of eto
has been reported to improve cardiac function in fatty acid–induced ischemic injury (45) and left ventricular performance in pressure-overloaded hearts (46–48); and it has also been tested in limited clinical
trials in patients with congestive heart failure, demonstrating improved ejection fraction and cardiac output (49, 50). In our studies, we did not observe any further heart allograft survival benefit in Ccr2–/– HTx,
suggesting that the efficacy of eto is dependent on the presence of Ccr2-expressing cells in the recipient.
Of note, the mouse model of heterotopic HTx results in a “nonfunctional” graft, where blood flows from
the recipient aorta into the donor ascending aorta, supplying the coronary arteries. Blood then drains
into the right atrium via the coronary sinus, which is then pumped into the right ventricle and, subsequently, enters the recipient inferior vena cava through the pulmonary artery. Coronary supply of arterial
JCI Insight 2022;7(7):e151596 https://doi.org/10.1172/jci.insight.151596
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Figure 6. Loss of Ccr2 in HTx recipients abrogates the effects of FAO inhibition. (A) Comparison of graft survival in vehicle-treated (ctrl-treated) or
etomoxir-treated (eto-treated) BALB → B6 CCR2–/– heart allografts. There was no statistical difference in survival (P = 0.7698 by Mantel-Cox test). (B–E)
Flow cytometric assessment in BALB → Ccr2–/– heart allografts 4 days after transplant, shown as a percentage of CD45+ cells (left graph) or live cells (right
graph; data for live cells from BALB → B6 HTx is replotted from Figures 1 and 2). (B) Pan T cells assessed by CD3+CD90.2+ cells (ctrl, n = 8; eto, n = 7 for BALB
→ B6 HTx; ctrl, n = 3; eto, n = 3 for BALB B6 Ccr2–/– HTx). (C) Activated T cells assessed by CD69+CD3+CD90.2+ cells (ctrl, n = 8; eto, n = 7 for BALB → B6 HTx;
ctrl, n = 3; eto, n = 3 for BALB →B6 Ccr2–/– HTx). (D) DCs assessed by CD11c+MHCII+CD64– cells (ctrl, n = 5; eto, n = 5 for BALB → B6 HTx; ctrl, n = 3; eto, n = 3
for BALB B6 Ccr2–/– HTx). (E) Macrophages assessed by CD11b+CD64+CD24– cells (ctrl, n = 8; eto, n = 7 for BALB → B6 HTx; ctrl, n = 3; eto, n = 3 for BALB → B6
Ccr2–/– HTx). (F) ELISPOT assay performed using splenocytes procured 4 days after transplantation from ctrl or eto-treated BALB B6 Ccr2–/– heart allografts.
Samples were stimulated with donor-derived (BALB) APCs and assessed for the production of IFN-γ (ctrl, n = 5; eto, n = 5). Data are shown as mean ± SEM.
*P < 0.05; **P < 0.01; ****P < 0.0001 (B–E, left graphs, and F) by t test or (B–E, right graphs) ANOVA and Bonferroni’s post hoc test.

blood reestablishes sinus rhythm in the transplanted heart after reperfusion; however, the left chambers
of the heart remain pressure underloaded (51).
One limitation of the current study is our use of eto as a pharmacological inhibitor of FAO. Eto has been
reported to have off-target effects on oxidative metabolism depending on dose and cell type (52, 53). We used
this drug because of our extensive previous experience with its pharmacokinetics and pharmacodynamics in
multiple cell types both in vitro and in vivo (35–37, 52, 53). By using a dose of 100 μM in vitro, we aimed to
avoid some of the off-target effects on complex I in the electron transport chain or coenzyme A homeostasis
that have been described at doses above 100 μM (specifically 200 μM and above) (41–43, 54). We further
confirmed that eto was able to inhibit FAO flux and Cpt1 activity at multiple doses in murine monocytes. In
our in vitro model of monocyte differentiation, we were able to demonstrate a significant reduction in FAO
upon treatment with eto; however, in vivo assessment of metabolic fluxes remains challenging. Off-target
effects of eto, and the doses which elicit them, are harder to investigate. However, our experiments using
Ccr2–/– recipient mice demonstrated abrogation of the effect of pharmacological inhibition of FAO and support our conclusion regarding the importance of FAO in monocyte differentiation. In addition, the role
of FAO in monocyte differentiation in the context of HTx in vivo was further verified using conditional
deletion of Cpt1a in monocytes. The mechanism whereby FAO regulates monocyte differentiation remains
to be determined. Our observation that both pharmacological inhibition of Cpt1 as well as genetic deletion
of Cpt1a can reduce monocyte-to-macrophage and monocyte-to-DC differentiation in heart allografts supports a role for FAO in these functions. Furthermore, investigation into the specific roles of FAO in DCs
and macrophages in allograft rejection is required. In addition to promoting alloimmunity and allograft
rejection, monocytic populations may also play an important role in limiting alloimmune responses. It has
previously been demonstrated that CD11b+CD115+Ly6C+ monocytes are required to maintain heart transplant tolerance induced by donor splenocyte transfusion in addition to anti-CD40L monoclonal antibody
(55). Early after transplantation, monocytes migrate from the bone marrow to the transplanted organ, where
they can prevent the initiation of adaptive immune responses that lead to allograft rejection and participate
in the development of Tregs. It has been reported that reducing monocyte-derived macrophages impairs
transplant tolerance, in part, through increasing both CD8+ T cell numbers and reducing Treg expansion
JCI Insight 2022;7(7):e151596 https://doi.org/10.1172/jci.insight.151596
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Figure 7. Genetic deletion of Cpt1a monocyte-derived DC and monocyte-derived macrophage differentiation in heart
allografts in vivo. (A) Schematic representation of adoptive transfer of 106 monocytes isolated from Cre–;Cpt1afl/fl
(WT) or Ccr2.CreER;Cpt1afl/fl (Ccr2ΔCpt1a) mice that were intravenously injected into HTx recipients (CD45.1+ BALB heart to
CD45.1+ B6 recipient) at the time of engraftment. (B and C) Flow cytometric assessment of transplanted hearts from
CD45.1+ BALB → CD45.1+ B6 allografts 4 days after HTx, adoptively transferred with WT or Ccr2ΔCpt1a monocytes. All cell
subtypes are shown as a percentage of CD45.2+ cells. (B) CD45.2+ DCs assessed by CD11c+MHCII+CD64– cells (WT,
n = 4; Ccr2ΔCpt1a, n = 4). (C) CD45.2+ macrophages assessed by CD11b+CD64+CD24– cells (WT, n = 4; Ccr2ΔCpt1a, n = 4). Data
are shown as mean ± SEM. **P < 0.01; ***P < 0.001 by t test.

(56, 57), suggesting that the role monocytes play in allogeneic immune responses may vary between acute
and tolerogenic settings. As our work demonstrates that inhibition of FAO can impair the differentiation
of monocyte-derived cells in acute HTx rejection, it would be of interest to further explore the role of FAO
in monocyte dynamics in tolerogenic settings. The potential clinical utilization of eto is unlikely, as clinical
trials for eto were halted in phase II due to unacceptably high liver transaminase levels and associated hepatotoxicity (58, 59). Nevertheless, our study highlights the potential clinical utility of other pharmacological
inhibitors of FAO, which warrants further investigation.

Methods
Animals. Six- to 10-week-old BALB (no. 000651), B6 (no. 000664), B6.SJL-PtprcaPepcb/BoyJ (known as
Pepboy, CD45.1+ B6 background; no. 002014), CByJ.SJL(B6)-Ptprca/J (CD45.1+ BALB background; no.
006584), B6.129S4-Ccr2tm1lfc/J (Ccr2–/–; no. 004999) and B6(Cg)-Cpt1atm1c(EUCOMM)Hmgu/RjnsJ (Cpt1afl/fl;
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refs. 36, 42; no. 032778) mice were purchased from The Jackson Laboratory. Ccr2.CreER transgenic mice
were a gift from Andrew Gelman (Washington University School of Medicine). Ccr2.CreER mice were
intercrossed with Cpt1afl/fl mice to generate Ccr2ΔCpt1a mice. Littermate Cre– Cpt1afl/fl mice were used as ctrls
(referred to herein as WT). Animals were bred and housed under standard conditions.
Reagents. Fluorochrome-conjugated antibodies used in this study are listed in Supplemental Table 1.
The LIVE/DEAD fixable violet dead cell stain kit was from Thermo Fisher Scientific. Brilliant Stain Buffer Plus 1000t and BD Horizon Fixable Viability Stain 510 were from BD Biosciences. Concanavalin A,
sodium hydroxide, trichloroacetic acid (TCA), (+)-eto sodium salt hydrate, tamoxifen, and other standard
laboratory chemicals were from MilliporeSigma.
Heterotopic heart transplant. Allogeneic (BALB → B6) and syngeneic (B6 → B6) heterotopic HTx
was performed as previously described (60, 61). Anesthesia was induced by a mixture of ketamine
(80–100 mg/kg) and xylazine HCl (8–12 mg/kg), administered i.p., and maintained with 1%–2% isoflurane gas, as required. Briefly, donor hearts were implanted into the abdominal cavity of recipient mice,
where the donor ascending aorta and pulmonary artery were anastomosed to the recipient infrarenal
aorta and inferior vena cava, respectively. Donor hearts were maintained on ice between procurement
and implantation, and cold ischemic times were less than 60 minutes. Heart transplant recipients were
administered either vehicle (H2O) or eto (20 mg/kg) daily by i.p. injection. Function of transplanted
hearts was assessed by daily direct palpation along the abdomen adjacent to the implantation site until
cessation of palpable heartbeat. Heart graft function was assessed using the following scale: +++, soft
graft with strong contraction; ++, mild turgor and mild contraction; +, hard turgor and weak contraction; –, no palpable contraction. Cessation of palpable heartbeat was verified at time of sacrifice by
laparotomy. For experiments involving Ccr2–/– mice, BALB donor hearts were transplanted into Ccr2–/–
recipient mice. For experiments involving adoptive transfer of WT or Ccr2ΔCpt1a monocytes, CD45.1+
BALB donor hearts were transplanted into CD45.1+ B6 recipient mice.
Monocyte isolation, adoptive transfer of monocytes, and in vitro differentiation. Bone marrow–derived monocytes were obtained from long bones using the MACS Monocyte Isolation Kit (Miltenyi Biotec) following
the manufacturer’s protocol. For adoptive transfer experiments, 107 B6 CD45.1, monocytes were intravenously injected at time of HTx (62). For monocyte differentiation assays, 106 monocytes were cultured in
RPMI complete media (Invitrogen) supplemented with 10% FBS, penicillin/streptomycin (Invitrogen; 120
units/mL and 100 μg/mL, respectively) and 0.05 mM 2-mercaptoethanol. Stimulation of monocytes to
differentiate toward a DC or macrophage lineage was achieved by culturing with GM-CSF (25 ng/mL,
Miltenyi Biotec) + IL-4 (25 ng/mL, Miltenyi Biotec) or M-CSF (100 ng/mL, Miltenyi Biotec), respectively.
Monocytes were treated with 100 μM eto for indicated experiments.
Flow cytometry. Spleen and mediastinal lymph nodes were procured and rinsed with PBS. Then, the tissue was minced and digested with washing with 0.5 mg/mL collagenase I (MilliporeSigma) + 60 units/mL
DNase I (MilliporeSigma) in DMEM, centrifuged, and filtered through a 70 μm filter. Then, RBC lysis buffer (MilliporeSigma) was used, followed by a final centrifugation step and freezing using CTL-Cryo ABC
Freezing Kit (Cellular Technology Limited [CTL]). Hearts were procured, perfused with cold PBS, and then
minced and digested with 450 units/mL collagenase I (MilliporeSigma) + 60 units hyaluronidase type 1-s
(MilliporeSigma) + 60 units/mL Dnase I in DMEM. The tissue in digestion solution was then centrifuged
and filtered through a 40 μm filter, followed by RBC lysis and a final centrifugation step and freezing using
CTL-Cryo ABC Freezing Kit (CTL). Flow cytometry was performed as previously described (63) using either
a BD LSR Fortessa or a BD X-20 BD (BD Biosciences). Representative flow plots in the figures illustrate the
distribution of the target population, which is presented in the associated graph(s) relative to CD45+ or live
cells, unless otherwise indicated. Flow cytometry data were analyzed by FlowJo software (version 10.71).
For identification of total T cells, we used the following gating strategy: FSC/SSC, single live cells,
CD45+, CD3+CD90.2+, CD69+, CD4+, CD8+, and Foxp3+CD4+ populations were identified from total T
cell pools. For identification of DCs, we used the following gating strategy: FSC/SSC, live cells, CD45+,
and CD11c+MHCII+. For identification of macrophages, we used the following gating strategy: FSC/SSC,
single live cells, CD45+, CD24–, and CD11b+CD64+.
For adoptive transfer experiments, the following gating strategy was used for CD45.1+ DCs: FSC/SSC,
single live cells, CD45+, CD45.1+, CD64–, and CD11c+MHCII+. The following gating strategy was used
for macrophages: FSC/SSC, single live cells, CD45+, CD45.1+, CD24–, and CD64+CD11b+. Similar gating
strategies were used for the assessment of in vitro monocyte differentiation.
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For experiments involving adoptive transfer of WT or Ccr2ΔCpt1a monocytes, the following gating strategy was used for CD45.2+ DCs: FSC/SSC, single live cells, CD45+, CD45.2+, CD64–, and CD11c+MHCII+.
The following gating strategy was used for CD45.2+ macrophages: FSC/SSC, single live cells, CD45+,
CD45.2+, CD24–, and CD11b+CD64+.
ELISPOT. Precoated strips with antibodies directed against mouse IFN-γ, TNF-α, or IL-2 were purchased from CTL. Splenocytes were obtained from HTx recipients, rinsed with PBS, and then the tissue
was minced and digested with 0.5 mg/mL collagenase I (MilliporeSigma) + 60 units/mL DNase I (MilliporeSigma) in DMEM, centrifuged, and filtered through a 70 μm filter. Then, RBC lysis buffer (MilliporeSigma) was used, followed by a final centrifugation step and freezing using the CTL-Cryo ABC Freezing Kit (CTL). Media only and 5 μg/mL Concanavalin A (MilliporeSigma) were used as negative and
positive ctrls, respectively. Isolated splenocytes from BALB or B6 mice were irradiated with 20 Gy using an
X-RAD 320 Biological Irradiator (Precision X-Ray) and used as “activated” APCs. Splenocytes (100,000
cells) were coincubated with positive ctrl, negative ctrl, or activated APCs (100,000 cells) and cultured in
CTL test serum-free media supplemented with penicillin/streptomycin (Invitrogen; 120 units/mL and 100
μg/mL, respectively) and 2 mM L-glutamine (Invitrogen). 2–3 technical replicate wells were used for each
condition, and n numbers represent samples from individual HTx. Single-color ELISPOT assays were performed following the manufacturer’s specifications, and plates were dried, scanned, and analyzed using an
Immunospot S6 Universal Analyzer (CTL).
Histology. Tissues were procured and fixed in 4% paraformaldehyde before embedding in OCT for
cryosections or processed for paraffin embedding. 5 μm sections were stained with hematoxylin and
eosin to assess histopathological changes.
Radioisotope tracer experiments. 50,000 cells per well were seeded and allowed to attach before gentle
washing and incubation for 48 hours in media containing 0.4 μCi/mL (24.24 nM final concentration)
[5-3H]glucose (Perkin Elmer) or 2 μCi/mL (66.67 nM final concentration) [9,10-3H]palmitate (Perkin
Elmer) for assessment of glycolytic or FAO flux, respectively. For FAO flux assays, 50 μM L-carnitine solution (MilliporeSigma) was supplemented to the media. To assess the production of 3H2O after a cumulative
48 hours of drug treatment, media was transferred to glass vials and sealed with rubber stoppers. 3H2O was
captured in hanging wells within the glass vials containing Whatman filter paper soaked with equivolume
H2O over a period of 48 hours at 37°C to reach saturation. Radioactivity for radioisotope tracer studies was
determined by liquid scintillation counting using a Beckman Coulter LS6500 scintillation counter.
Cpt1 activity assay. Cpt1 activity was performed on isolated mitochondria from murine monocytes.
Briefly, bone marrow–derived monocytes were obtained from long bones using the MACS Monocyte Isolation Kit (Miltenyi Biotec) following the manufacturer’s protocol, and then mitochondria were isolated
using a mitochondria isolation kit (Thermo Fisher Scientific). Isolated mitochondria were coincubated
with radioisotope-labeled 9,10-[3H]palmitic and 1-[14C]palmitoyl-CoA in an assay solution containing
20 mM HEPES, 75 mM KCl, 2 mM KCN, 1% fatty acid–free BSA, and 0.25 mM L-carnitine, adapted from
previous publications (64–66). After incubating for 3 minutes at 37°C, the reaction was quenched with
3 M TCA, spun down at 12,000g for 5 minutes, and then washed with 2 mM TCA and centrifuged again,
before removing the supernatant and extracting the mitochondrial pellet for liquid scintillation counting
using a Beckman Coulter LS6500 scintillation counter. The endogenous Cpt1 inhibitor malonyl-CoA
(MilliporeSigma) was used as a positive ctrl.
Proliferation assay. Thymidine incorporation assay was used to assess cell proliferation. Briefly,
10,000 cells per well were seeded and incubated with 1 μCi/mL [3H]thymidine (Perkin Elmer) for specified time periods. Cells were fixed with 100% ethanol for 15 minutes at 4°C and then precipitated
with 10% TCA (MilliporeSigma) and lysed with 0.1 N NaOH (MilliporeSigma). The amount of [3H]
thymidine incorporated into DNA was measured by liquid scintillation counting. T cells were isolated
from the spleens of HTx recipients using the pan T cell isolation kit (Miltenyi Biotec) and then cultured
in RPMI (Invitrogen) supplemented with 10% FBS, penicillin/streptomycin (Invitrogen; 120 units/
mL and 100 μg/mL, respectively), 0.05 mM 2-mercaptoethanol, and 20 units/mL recombinant IL-2
(Miltenyi Biotec). Monocytes were cultured as indicated above. T cells or monocytes were treated with
100 μM eto for indicated experiments.
Cytotoxicity assessment. The Cytotoxicity Detection Kit (Roche CustomBiotech), which quantifies cytotoxicity/cytolysis based on the measurement of LDH release from damaged cells, was used to assess the
effects of eto on monocyte viability, as per the manufacturer’s protocol.
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Statistics. All data are expressed as mean ± SEM, unless otherwise indicated. Two-tailed Student’s t test
was used for 2-group comparisons. For multiple group analysis, 1-way ANOVA with Bonferroni’s post hoc
test was used to calculate statistical significance. Log-rank (Mantel-Cox) test was used for survival curve
comparison. P values of less than 0.05 were considered statistically significant. Statistical analysis and
graphics were performed using GraphPad Prism software and Microsoft Excel.
Study approval. Animal experiments were conducted in accordance with an approved Washington University School of Medicine Institutional Animal Care and Use Committee protocol (no. 20190173; no. 20190174).
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